Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    A unified Locations section has been added, listing Connecticut and Texas. The prior separate Connecticut Locations and Texas Locations sections were removed.
    Difference
    0.3%
    Check dated 2025-12-23T17:32:33.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    50 days ago
    Change Detected
    Summary
    Site revision note shows v3.3.2 added and v3.2.0 removed, indicating a minor update to the platform. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T20:50:31.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Removed the government funding/operating status notice banner from the page.
    Difference
    0.4%
    Check dated 2025-11-17T18:13:00.000Z thumbnail image
  7. Check
    71 days ago
    Change Detected
    Summary
    No significant changes to core study content were detected between the two screenshots; only minor formatting, text edits, or timestamp updates appear. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T12:53:43.000Z thumbnail image
  8. Check
    100 days ago
    Change Detected
    Summary
    - Added a government operations notice and operating details, plus a new v3.2.0 revision. - Removed the previous v3.1.0 revision.
    Difference
    3%
    Check dated 2025-10-05T17:39:37.000Z thumbnail image
  9. Check
    107 days ago
    Change Detected
    Summary
    Update to version v3.1.0 with removal of the specific resource for head and neck squamous cell carcinoma; overall content impact is minor.
    Difference
    0.5%
    Check dated 2025-09-28T11:16:23.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.